SETBP1 and melanoma: Shared between the ancestries, we found shortened TTL to be associated with acquired variation within the DNA replication tumour-associated gene SETBP1. Having previously reported SETBP1 to be significantly mutated in African-derived tumours9, this new PCa driver36 showing favourable outcomes in response to immune checkpoint inhibitor treatment in melanoma patients37, warrants further investigation on the clinical impact for patients presenting with shortened TTL and SETBP1 mutant prostate tumours.